Summary & Overview

HCPCS G9034: Zanamivir Inhalation Powder, Inhaler, 10 mg

HCPCS Level II code G9034 represents brand-name zanamivir inhalation powder, supplied and administered via inhaler in a Medicare-approved demonstration project, billed per 10 mg. This code is significant nationally as it documents use of an inhaled antiviral in structured demonstration settings, supporting tracking of novel or limited-use therapies and informing coverage and utilization discussions. Payers commonly considered in national analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare.

Readers will learn the clinical and billing context for G9034, including the service type (medication administration via inhalation) and typical sites of service (outpatient and ambulatory inhalation or therapy clinics). The publication summarizes benchmark considerations, coding and billing context for demonstration-project drugs, and policy implications for payer coverage and claims processing. It also outlines where to find related billing guidance and what to expect in payer adjudication pathways for demonstration project medications. Data not available in the input is noted where applicable, and readers will find a concise reference for clinicians, billing staff and policy analysts seeking a national overview of HCPCS Level II code G9034.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9034HCPCS Level IIzanamivirinhalation therapymedication administrationdemonstration projectoutpatient careantiviral

Billing Code Overview

HCPCS Level II code G9034 describes Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg, intended for use in a Medicare-approved demonstration project. The service involves provision and administration of a prescription antiviral in inhalation powder form delivered via a patient inhaler device.

Service type: Medication administration / outpatient inhalation therapy
Typical site of service: Outpatient clinic, infusion or inhalation therapy clinic, or other ambulatory care settings where inhaled antiviral therapy is supplied and administered

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult presenting with acute influenza-like illness during an influenza season or within 48 hours of symptom onset, for whom neuraminidase inhibitor therapy is indicated and inhaled zanamivir is appropriate. The clinical workflow begins with triage and assessment of symptoms (fever, cough, myalgias), rapid influenza diagnostic testing or clinical diagnosis, medication reconciliation to evaluate inhaler use and respiratory status (assess for reactive airway disease or bronchospasm risk), and informed consent for participation in a Medicare-approved demonstration project if applicable. The medication G9034 (zanamivir, inhalation powder, per 10 mg) is prepared and dispensed through the approved inhaler device by a pharmacy or clinic staff, with instruction provided on proper inhaler technique and observation for immediate adverse reactions. Typical monitoring includes assessment of respiratory status post-administration and documentation in the medical record of dose, lot number, administration route (inhalation), and participation in the demonstration project. Usual sites of service include outpatient clinic, urgent care, ambulatory infusion/medication clinic, and hospital outpatient pharmacy when administered as part of a monitored clinical program.

Coding Specifications

Modifier	Description	When to Use
`59`	Distinct procedural service	When zanamivir administration is a separate, distinct service from other procedures on the same day
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day	When an E/M visit is performed and documented separately from zanamivir administration
`76`	Repeat procedure or service by same physician	If the inhalation administration is repeated during the same encounter
`77`	Repeat procedure by another physician	If a different clinician repeats the inhalation administration during the same encounter
`GT`	Via interactive audio and video telecommunication (historical)	When billed services related to the demonstration project include telehealth components (use only per payer rules)
`Q0`	Investigational clinical service provided in a clinical research study that is non-routine	When administration occurs under an approved clinical research protocol consistent with payer policy
`Q1`	Routine clinical service provided in a clinical research study	When the service is considered routine care within the Medicare-approved demonstration project
`JW`	Drug amount discarded/not administered to any patient	When part of a multi-dose vial or unit dose is wasted and must be reported (if applicable to drug handling)
`XE`	Separate encounter, a distinct encounter	When the service occurs during a completely separate encounter from other services billed the same day
`XP`	Separate practitioner, a different practitioner performed the service	When a different practitioner provides the inhalation administration than the one billing other services

Taxonomy Code	Specialty	Notes
`208D00000X`	Family Medicine	Primary care clinicians who diagnose influenza and administer or coordinate antiviral therapy
`207Q00000X`	Infectious Disease	Specialists who manage antiviral therapies and oversee demonstration protocols
`207L00000X`	Pulmonary Disease	Evaluate respiratory suitability for inhaled therapy and manage adverse respiratory events
`363LP0800X`	Pharmacy	Pharmacists who prepare, dispense, and instruct patients on inhaler use in ambulatory settings
`163WW0200X`	Emergency Medicine	Clinicians in urgent care or ED who may initiate inhaled antiviral therapy during acute presentations

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J10.1`	Influenza due to other identified influenza virus with other respiratory manifestations	Primary indication for antiviral therapy including inhaled zanamivir when influenza virus is identified
`J11.1`	Influenza due to unidentified influenza virus with other respiratory manifestations	Used when clinical diagnosis of influenza is made without laboratory confirmation
`J06.9`	Acute upper respiratory infection, unspecified	Symptomatic presentations that may prompt testing and consideration of antiviral therapy
`J18.9`	Pneumonia, unspecified organism	Secondary or complicating lower respiratory infection where antiviral therapy assessment may be part of management
`J45.909`	Unspecified asthma, uncomplicated	Important comorbidity to document because inhaled zanamivir can provoke bronchospasm and requires caution
`R05`	Cough	Symptom code often present in patients receiving antiviral inhalation therapy
`R50.9`	Fever, unspecified	Common presenting symptom that supports evaluation for influenza and potential antiviral treatment

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M code when assessment and decision to administer zanamivir occur during an outpatient visit
`99070`	Supplies and materials (e.g., drugs, gloves, syringes) provided by the physician over and above those usually included with the office visit	Used to report the inhaler device or specific drug supplies when required by payer policy
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Occasionally used by some practices to report administration time or an administration-related service when local policy aligns (verify payer guidance)
`94760`	Noninvasive ear or pulse oximetry for oxygen saturation (per encounter)	Used to document monitoring of oxygenation or respiratory status during or after inhaled therapy in patients at risk
`G0127`	Screening mammography, bilateral; only example of a G-code included for illustration (not typically related)	Data not applicable clinically to zanamivir administration but included here only when payers require demonstration-project specific G-codes (check project requirements)